menu search

Evelo biosciences provides clinical and business updates

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate ob...

February 1, 2023, 12:30 pm

Arcutis presents new phase 2 long-term data showing sustained efficacy and clearance for a median of 10 months with roflumilast cream in adults with chronic plaque psoriasis

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any t...

January 14, 2023, 9:00 am

Roivant sciences: a solid year of progress and good prospects for 2023

Roivant's differentiated approach to the drug development business has been hit and miss. The company's subsidiary Dermavant won a first approval this...

December 20, 2022, 3:32 pm

Can-fite biopharma shares jump after piclidenoson data in psoriasis trial

Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate ...

June 29, 2022, 7:57 am

Arcutis: roflumilast has excellent data and high probability of fda approval

Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psor...

April 5, 2022, 5:01 pm

Can-fite biopharma flags delay in piclidenoson data readout from psoriasis study

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort ...

March 8, 2022, 8:35 am

Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines

Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...

February 7, 2022, 7:54 am

Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines

Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...

February 7, 2022, 7:54 am

Evelo biosciences' psoriasis candidate shows reductions in inflammatory cytokines

Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed E...

February 7, 2022, 7:54 am

Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi

AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...

February 2, 2022, 7:46 am

Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi

AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...

February 2, 2022, 7:46 am

Abbvie forecasts 2022 profit above estimates on strong sales of botox, skyrizi

AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer ...

February 2, 2022, 7:46 am


Search within

Pages Search Results: